アルブミンの世界市場2022-2032:機会分析・産業予測

◆英語タイトル:Albumin Market by Type (Human Serum, Bovine Serum, and Recombinant HSA), Form (Lyophilisation/Powder and Liquid/Solution), Application (Therapeutics, Drug Formulations, Vaccine, and Others), Grade (Technical and Diagnostic Grade, Research/Reagent Grade, and Food Grade), and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2022-2032

Research Diveが発行した調査報告書(RDV23MA013)◆商品コード:RDV23MA013
◆発行会社(リサーチ会社):Research Dive
◆発行日:2022年9月22日
◆ページ数:250
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:生命科学
◆販売価格オプション(消費税別)
Single UserUSD5,700 ⇒換算¥866,400見積依頼/購入/質問フォーム
5 UserUSD8,700 ⇒換算¥1,322,400見積依頼/購入/質問フォーム
Enterprise UserUSD10,700 ⇒換算¥1,626,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

リサーチ・ダイブ社では、世界のアルブミン市場規模が2021年5,394.9百万ドルから2032年には10,239.0百万ドルになり、年平均6.1%成長すると推測しています。本調査報告書では、アルブミンの世界市場について多面的に調べ、調査手法、調査範囲、エグゼクティブサマリー、市場概要、種類別(ヒト血清、ウシ血清、組換えHSA)分析、形態別(凍結乾燥/粉末、液体/溶液)分析、用途別(治療、製剤、ワクチン、その他)分析、グレード別(工業&診断、研究/試薬、食品)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ)分析、競争状況などの内容を掲載しています。尚、企業情報として、Baxter International Inc., China Biologic Products Holdings, Inc., CSL Limited, Grifols, S.A., Merck KGaA, Novozymes, Octapharma AG, Takeda Pharmaceuticals Company Limited, Thermo Fisher Scientific, and Ventria Bioscience Inc.などが記載されています。
・調査手法
・調査範囲
・エグゼクティブサマリー
・市場概要
・世界のアルブミン市場規模:種類別
- ヒト血清の市場規模
- ウシ血清の市場規模
- 組換えHSAの市場規模
・世界のアルブミン市場規模:形態別
- アルブミン凍結乾燥/粉末の市場規模
- アルブミン液体/溶液の市場規模
・世界のアルブミン市場規模:用途別
- 治療用アルブミンの市場規模
- 製剤用アルブミンの市場規模
- その他用途の市場規模
- 治療用アルブミンの市場規模
・世界のアルブミン市場規模:グレード別
- 工業&診断における市場規模
- 研究/試薬における市場規模
- 食品における市場規模
・世界のアルブミン市場規模:地域別
- 北米のアルブミン市場規模
- ヨーロッパのアルブミン市場規模
- アジア太平洋のアルブミン市場規模
- 中南米のアルブミン市場規模
- 中東/アフリカのアルブミン市場規模
・競争状況
・企業情報

According to Research Dive analysis, the global albumin market is anticipated to generate a revenue of $10,239.0 million by 2032, increasing from $5,394.9 million in 2021, at a healthy CAGR of 6.1%.

COVID-19 Impact on the Global Albumin Market:
The COVID-19 pandemic is predicted to have a positive impact on the expansion of the global albumin market. Albumin usage is rising as a result of an increase in the production of COVID-19 infection vaccines such as Covishield and Covaxin. For instance, according to the National Clinical Trial Registry, there are roughly ten planned and ongoing experiments using albumin to make COVID-19 vaccines. As a result, albumin use has increased, which is anticipated to drive the albumin market throughout the course of the forecasted period. As a result, it is anticipated that rising product approvals and recent developments from significant competitors will fuel market growth.

Albumin Market Analysis:
Albumin is a viable alternative for use in a variety of application fields such as therapeutics, drug formulations, and the vaccine because it has several benefits and uses. Albumin is primarily used in a variety of applications as a nutrient supply in cell culture media formulations and as a protein stabilizing excipient in biologic medication formulations, especially for those that are lyophilized. Albumin is added to cell culture media to enhance the general health of cells, and promote cell growth in in-vitro lab environments. Albumin not only transports nutrients like hormones and growth factors but also binds to free radicals and poisons like copper to prevent cell damage. Additionally, albumin binds to proteins and functions as a buffer. It also stabilizes hormones, growth peptides, and other media components. These are the main variables that are projected to increase the market share for albumin over the analysis period.

Despite the increasing incidence of hypoalbuminemia and hypovolemia throughout the world, the use of albumin is limited due to factors including severe government rules and a lack of therapeutic products. The rigorous government regulations imposed on the development of therapeutic applications are one of the major problems limiting market expansion.
It is projected that increased company’s R&D initiatives will benefit the market. For instance, a study entitled ‘Albumin Administration is Efficacious in the Management of Patients with Cirrhosis: A Systematic Review of the Literature’ published in May 2020, asserted that albumin is safe and effective for treating or preventing a variety of complications arising from cirrhosis, such as ascites, paracentesis-induced circulatory dysfunction, infections, and hepatorenal syndrome, thus boosting the market and increasing demand for albumin. All these aspects are predicted to boost the albumin market size in the upcoming years.
Based on type, the human serum sub-segment accounted for the highest market share in 2021. Human serum one of the most prevalent proteins in human plasma is albumin. HSA is a multifunctional, nonglycosylated, negatively charged, extracellular plasma protein. Additionally, Hypoalbuminemia can be brought on by a variety of conditions, including cancer, sepsis, trauma, heart failure, liver failure, and others.

Based on form, the liquid/solution sub-segment accounted for the highest market share in 2021. Plasma contains the protein albumin, which is produced by the liver (the clear liquid portion of your blood). To manufacture pharmaceutical albumin, proteins from human blood plasma are utilized.

Based on application, the vaccine sub-segment is predicted to be the fastest growing sub-segment by 2032. A vaccination is a biological preparation created to create acquired immunity for a particular disease. Typically, vaccines either eliminate or weaken the disease-causing pathogen, its surface proteins, or its toxins.

Based on grade, the technical and diagnostic grade sub-segment accounted for the highest market share in 2021. The technical & diagnostic grade of albumin is generally utilized as a blocking agent in biotechnology applications. This grade’s products are mostly used in cell culture-related applications.

Based on geographical scope, the Asia-Pacific albumin market is anticipated to rise at a growth rate by 2032. The fast-growing healthcare infrastructure in the Asia-Pacific region and the population’s rising disposable income are both factors responsible for the regional expansion.
The companies involved in the global albumin market are Baxter International Inc., China Biologic Products Holdings, Inc., CSL Limited, Grifols, S.A., Merck KGaA, Novozymes, Octapharma AG, Takeda Pharmaceuticals Company Limited, Thermo Fisher Scientific, and Ventria Bioscience Inc.”

❖ レポートの目次 ❖

1.Research Methodology

1.1.Desk Research
1.2.Real time insights and validation
1.3.Forecast model
1.4.Assumptions and forecast parameters
1.5.Market size estimation
1.5.1.Top-down approach
1.5.2.Bottom-up approach

2.Report Scope

2.1.Market definition
2.2.Key objectives of the study
2.3.Report overview
2.4.Market segmentation
2.5.Overview of the impact of COVID-19 on global albumin market

3.Executive Summary

4.Market Overview

4.1.Introduction
4.2.Growth impact forces

4.2.1.Drivers
4.2.2.Restraints
4.2.3.Opportunities

4.3.Market value chain analysis

4.3.1.List of raw material suppliers
4.3.2.List of manufacturers
4.3.3.List of distributors

4.4.Innovation & sustainability matrices

4.4.1.Technology matrix
4.4.2.Regulatory matrix

4.5.Porter’s five forces analysis

4.5.1.Bargaining power of suppliers
4.5.2.Bargaining power of consumers
4.5.3.Threat of substitutes
4.5.4.Threat of new entrants
4.5.5.Competitive rivalry intensity

4.6.PESTLE analysis

4.6.1.Political
4.6.2.Economical
4.6.3.Social
4.6.4.Technological
4.6.5.Environmental

4.7.Impact of COVID-19 on albumin market

4.7.1.Pre-covid market scenario
4.7.2.Post-covid market scenario

5.Albumin Market Analysis, by Type

5.1.Overview
5.2.Human Serum

5.2.1.Definition, key trends, growth factors, and opportunities
5.2.2.Market size analysis, by region, 2021-2032
5.2.3.Market share analysis, by country, 2021-2032

5.3.Bovine Serum

5.3.1.Definition, key trends, growth factors, and opportunities
5.3.2.Market size analysis, by region, 2021-2032
5.3.3.Market share analysis, by country, 2021-2032

5.4.Recombinant HSA

5.4.1.Definition, key trends, growth factors, and opportunities
5.4.2.Market size analysis, by region, 2021-2032
5.4.3.Market share analysis, by country, 2021-2032

5.5.Research Dive Exclusive Insights

5.5.1.Market attractiveness
5.5.2.Competition heatmap

6.Albumin Market Analysis, by Form

6.1.Lyophilisation/Powder

6.1.1.Definition, key trends, growth factors, and opportunities
6.1.2.Market size analysis, by region, 2021-2032
6.1.3.Market share analysis, by country, 2021-2032

6.2.Liquid/Solution

6.2.1.Definition, key trends, growth factors, and opportunities
6.2.2.Market size analysis, by region, 2021-2032
6.2.3.Market share analysis, by country, 2021-2032

6.3.Research Dive Exclusive Insights

6.3.1.Market attractiveness
6.3.2.Competition heatmap

7.Albumin Market Analysis, by Application

7.1.Therapeutics

7.1.1.Definition, key trends, growth factors, and opportunities
7.1.2.Market size analysis, by region, 2021-2032
7.1.3.Market share analysis, by country, 2021-2032

7.2.Drug Formulations

7.2.1.Definition, key trends, growth factors, and opportunities
7.2.2.Market size analysis, by region, 2021-2032
7.2.3.Market share analysis, by country, 2021-2032

7.3.Vaccine

7.3.1.Definition, key trends, growth factors, and opportunities
7.3.2.Market size analysis, by region, 2021-2032
7.3.3.Market share analysis, by country, 2021-2032

7.4.Others

7.4.1.Definition, key trends, growth factors, and opportunities
7.4.2.Market size analysis, by region, 2021-2032
7.4.3.Market share analysis, by country, 2021-2032

7.5.Research Dive Exclusive Insights

7.5.1.Market attractiveness
7.5.2.Competition heatmap

8.Albumin Market Analysis, by Grade

8.1.Technical and Diagnostic Grade

8.1.1.Definition, key trends, growth factors, and opportunities
8.1.2.Market size analysis, by region, 2021-2032
8.1.3.Market share analysis, by country, 2021-2032

8.2. Research/Reagent Grade

8.2.1.Definition, key trends, growth factors, and opportunities
8.2.2.Market size analysis, by region, 2021-2032
8.2.3.Market share analysis, by country, 2021-2032

8.3.Food Grade

8.3.1.Definition, key trends, growth factors, and opportunities
8.3.2.Market size analysis, by region, 2021-2032
8.3.3.Market share analysis, by country, 2021-2032

8.4.Research Dive Exclusive Insights

8.4.1.Market attractiveness
8.4.2.Competition heatmap

9.Albumin Market, by Region

9.1.North America

9.1.1.U.S.

9.1.1.1.Market size analysis, by Type, 2021-2032
9.1.1.2.Market size analysis, by Form, 2021-2032
9.1.1.3.Market size analysis, by Application, 2021-2032
9.1.1.4.Market size analysis, by Grade, 2021-2032

9.1.2.Canada

9.1.2.1.Market size analysis, by Type, 2021-2032
9.1.2.2.Market size analysis, by Form, 2021-2032
9.1.2.3.Market size analysis, by Application, 2021-2032
9.1.2.4.Market size analysis, by Grade, 2021-2032

9.1.3.Mexico

9.1.3.1.Market size analysis, by Type, 2021-2032
9.1.3.2.Market size analysis, by Form, 2021-2032
9.1.3.3.Market size analysis, by Application, 2021-2032
9.1.3.4.Market size analysis, by Grade, 2021-2032

9.1.4.Research Dive Exclusive Insights

9.1.4.1.Market attractiveness
9.1.4.2.Competition heatmap

9.2.Europe

9.2.1.Germany

9.2.1.1.Market size analysis, by Type, 2021-2032
9.2.1.2.Market size analysis, by Form, 2021-2032
9.2.1.3.Market size analysis, by Application, 2021-2032
9.2.1.4.Market size analysis, by Grade, 2021-2032

9.2.2.UK

9.2.2.1.Market size analysis, by Type, 2021-2032
9.2.2.2.Market size analysis, by Form, 2021-2032
9.2.2.3.Market size analysis, by Application, 2021-2032
9.2.2.4.Market size analysis, by Grade, 2021-2032

9.2.3.France

9.2.3.1.Market size analysis, by Type, 2021-2032
9.2.3.2.Market size analysis, by Form, 2021-2032
9.2.3.3.Market size analysis, by Application, 2021-2032
9.2.3.4.Market size analysis, by Grade, 2021-2032

9.2.4.Spain

9.2.4.1.Market size analysis, by Type, 2021-2032
9.2.4.2.Market size analysis, by Form, 2021-2032
9.2.4.3.Market size analysis, by Application, 2021-2032
9.2.4.4.Market size analysis, by Grade, 2021-2032

9.2.5.Italy

9.2.5.1.Market size analysis, by Type, 2021-2032
9.2.5.2.Market size analysis, by Form, 2021-2032
9.2.5.3.Market size analysis, by Application, 2021-2032
9.2.5.4.Market size analysis, by Grade, 2021-2032

9.2.6.Rest of Europe

9.2.6.1.Market size analysis, by Type, 2021-2032
9.2.6.2.Market size analysis, by Form, 2021-2032
9.2.6.3.Market size analysis, by Application, 2021-2032
9.2.6.4.Market size analysis, by Grade, 2021-2032

9.2.7.Research Dive Exclusive Insights

9.2.7.1.Market attractiveness
9.2.7.2.Competition heatmap
9.3.Asia-Pacific

9.3.1.China

9.3.1.1.Market size analysis, by Type, 2021-2032
9.3.1.2.Market size analysis, by Form, 2021-2032
9.3.1.3.Market size analysis, by Application, 2021-2032
9.3.1.4.Market size analysis, by Grade, 2021-2032

9.3.2.Japan

9.3.2.1.Market size analysis, by Type, 2021-2032
9.3.2.2.Market size analysis, by Form, 2021-2032
9.3.2.3.Market size analysis, by Application, 2021-2032
9.3.2.4.Market size analysis, by Grade, 2021-2032

9.3.3.India

9.3.3.1.Market size analysis, by Type, 2021-2032
9.3.3.2.Market size analysis, by Form, 2021-2032
9.3.3.3.Market size analysis, by Application, 2021-2032
9.3.3.4.Market size analysis, by Grade, 2021-2032

9.3.4.Australia

9.3.4.1.Market size analysis, by Type, 2021-2032
9.3.4.2.Market size analysis, by Form, 2021-2032
9.3.4.3.Market size analysis, by Application, 2021-2032
9.3.4.4.Market size analysis, by Grade, 2021-2032

9.3.5.South Korea

9.3.5.1.Market size analysis, by Type, 2021-2032
9.3.5.2.Market size analysis, by Form, 2021-2032
9.3.5.3.Market size analysis, by Application, 2021-2032
9.3.5.4.Market size analysis, by Grade, 2021-2032

9.3.6.Rest of Asia-Pacific

9.3.6.1.Market size analysis, by Type, 2021-2032
9.3.6.2.Market size analysis, by Form, 2021-2032
9.3.6.3.Market size analysis, by Application, 2021-2032
9.3.6.4.Market size analysis, by Grade, 2021-2032

9.3.7.Research Dive Exclusive Insights

9.3.7.1.Market attractiveness
9.3.7.2.Competition heatmap

9.4.LAMEA

9.4.1.Brazil

9.4.1.1.Market size analysis, by Type, 2021-2032
9.4.1.2.Market size analysis, by Form, 2021-2032
9.4.1.3.Market size analysis, by Application, 2021-2032
9.4.1.4.Market size analysis, by Grade, 2021-2032

9.4.2.Saudi Arabia

9.4.2.1.Market size analysis, by Type, 2021-2032
9.4.2.2.Market size analysis, by Form, 2021-2032
9.4.2.3.Market size analysis, by Application, 2021-2032
9.4.2.4.Market size analysis, by Grade, 2021-2032

9.4.3.UAE

9.4.3.1.Market size analysis, by Type, 2021-2032
9.4.3.2.Market size analysis, by Form, 2021-2032
9.4.3.3.Market size analysis, by Application, 2021-2032
9.4.3.4.Market size analysis, by Grade, 2021-2032

9.4.4.South Africa

9.4.4.1.Market size analysis, by Type, 2021-2032
9.4.4.2.Market size analysis, by Form, 2021-2032
9.4.4.3.Market size analysis, by Application, 2021-2032
9.4.4.4.Market size analysis, by Grade, 2021-2032

9.4.5.Rest of LAMEA

9.4.5.1.Market size analysis, by Type, 2021-2032
9.4.5.2.Market size analysis, by Form, 2021-2032
9.4.5.3.Market size analysis, by Application, 2021-2032
9.4.5.4.Market size analysis, by Grade, 2021-2032

9.4.6.Research Dive Exclusive Insights

9.4.6.1.Market attractiveness
9.4.6.2.Competition heatmap

10.Competitive Landscape

10.1.Top winning strategies, 2021

10.1.1.By strategy
10.1.2.By year
10.2.Strategic overview
10.3.Market share analysis, 2021

11.Company Profiles

11.1.Baxter International Inc.

11.1.1.Overview
11.1.2.Business segments
11.1.3.Product portfolio
11.1.4.Financial performance
11.1.5.Recent developments
11.1.6.SWOT analysis

11.2.China Biologic Products Holdings, Inc.

11.2.1.Overview
11.2.2.Business segments
11.2.3.Product portfolio
11.2.4.Financial performance
11.2.5.Recent developments
11.2.6.SWOT analysis

11.3.CSL Limited

11.3.1.Overview
11.3.2.Business segments
11.3.3.Product portfolio
11.3.4.Financial performance
11.3.5.Recent developments
11.3.6.SWOT analysis

11.4.Grifols, S.A.

11.4.1.Overview
11.4.2.Business segments
11.4.3.Product portfolio
11.4.4.Financial performance
11.4.5.Recent developments
11.4.6.SWOT analysis

11.5.Merck KGaA

11.5.1.Overview
11.5.2.Business segments
11.5.3.Product portfolio
11.5.4.Financial performance
11.5.5.Recent developments
11.5.6.SWOT analysis

11.6.Novozymes

11.6.1.Overview
11.6.2.Business segments
11.6.3.Product portfolio
11.6.4.Financial performance
11.6.5.Recent developments
11.6.6.SWOT analysis

11.7. Octapharma AG

11.7.1.Overview
11.7.2.Business segments
11.7.3.Product portfolio
11.7.4.Financial performance
11.7.5.Recent developments
11.7.6.SWOT analysis

11.8.Takeda Pharmaceuticals Company Limited

11.8.1.Overview
11.8.2.Business segments
11.8.3.Product portfolio
11.8.4.Financial performance
11.8.5.Recent developments
11.8.6.SWOT analysis

11.9.Thermo Fisher Scientific

11.9.1.Overview
11.9.2.Business segments
11.9.3.Product portfolio
11.9.4.Financial performance
11.9.5.Recent developments
11.9.6.SWOT analysis

11.10.Ventria Bioscience Inc.

11.10.1.Overview
11.10.2.Business segments
11.10.3.Product portfolio
11.10.4.Financial performance
11.10.5.Recent developments
11.10.6.SWOT analysis

12.Appendix

12.1.Parent & peer market analysis
12.2.Premium insights from industry experts
12.3.Related reports”



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ アルブミンの世界市場2022-2032:機会分析・産業予測(Albumin Market by Type (Human Serum, Bovine Serum, and Recombinant HSA), Form (Lyophilisation/Powder and Liquid/Solution), Application (Therapeutics, Drug Formulations, Vaccine, and Others), Grade (Technical and Diagnostic Grade, Research/Reagent Grade, and Food Grade), and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2022-2032)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆